CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 727 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR FDA Approves Selinexor for Refractory or Relapsed Multiple Myeloma January 8, 2021 Trialling a new way to boost CAR T-cell therapy June 23, 2021 “After a fire and a pandemic, it felt amazing to finish... November 1, 2021 March is Colon Cancer Awareness Month March 11, 2021 Load more HOT NEWS Living With Stage 4 Lung Cancer: How Genomic Testing Is Helping... Inhibition of GDF-15 with Ponsegromab Results in Increased Weight Gain and... Belzutifan Shows a Significant Benefit Over Everolimus in Patients with Advanced... When You Have to Make Decisions for a Loved One With...
